Vertex Pharmaceuticals Incorporated VRTX stock has declined 8.9% in the past three months. The deterioration was due to soft first-quarter results, slower-than-expected uptake of its newer drugs as ...
At the 2025 Napa Valley Biotech Forum, JPMorgan analyst Jessica Fye walked away with a bullish tone after conversations with Vertex CEO Reshma Kewalramani and Senior Vice President of Investor ...
Vertex has a solid cystic fibrosis portfolio that generates billions of dollars in annual earnings -- and that’s set to continue for the long term. The biotech, expanding into other treatment areas, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback